Received Feb 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | UNK | — |
Incomplete course of vaccination; This non-serious case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a male patient who received Men B NVS (Bexsero) for prophylaxis. Previously administered products included Bexsero (The patient received first dose of Bexsero on 25-OCT-2023 with batch number 5AR2D and expiry date 00-DEC-2025) and Bexsero (The patient received second dose of Bexsero on 01-DEC-2023 with batch number 5AR2D and expiry date 00-DEC-2025). The patient did not receive the 3rd dose of Bexsero. The patient experienced incomplete course of vaccination (Verbatim: Incomplete course of vaccination). The outcome of the incomplete course of vaccination was not applicable. It was unknown if the reporter considered the incomplete course of vaccination to be related to Bexsero. It was unknown if the company considered the incomplete course of vaccination to be related to Bexsero. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date:20-JAN-2026 The patient did not receive third dose of Bexsero till the time of reporting. The reporter stated that she was confused, believed that both doses of Bexsero were administered in her son's left arm, and did not know whether the vaccines were given intramuscularly